Cargando…

Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis

Anti-VEGF drugs like ranibizumab can be used to treat retinopathy of prematurity (ROP) by halting the formation of abnormal blood vessels, or lasers can be used to burn the edges of the retina where these vessels are present. The objective is to compare the efficacy for ROP between ranibizumab and l...

Descripción completa

Detalles Bibliográficos
Autores principales: Alva, Niza, Martínez, Alex R., Ortiz-Saavedra, Brando, Montes-Madariaga, Elizbet S., Cotrina, Alonso, Caballero-Alvarado, José A., Sah, Ranjit, Barboza, Joshuan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436596/
https://www.ncbi.nlm.nih.gov/pubmed/37601137
http://dx.doi.org/10.3389/fped.2023.1202927
_version_ 1785092368746151936
author Alva, Niza
Martínez, Alex R.
Ortiz-Saavedra, Brando
Montes-Madariaga, Elizbet S.
Cotrina, Alonso
Caballero-Alvarado, José A.
Sah, Ranjit
Barboza, Joshuan J.
author_facet Alva, Niza
Martínez, Alex R.
Ortiz-Saavedra, Brando
Montes-Madariaga, Elizbet S.
Cotrina, Alonso
Caballero-Alvarado, José A.
Sah, Ranjit
Barboza, Joshuan J.
author_sort Alva, Niza
collection PubMed
description Anti-VEGF drugs like ranibizumab can be used to treat retinopathy of prematurity (ROP) by halting the formation of abnormal blood vessels, or lasers can be used to burn the edges of the retina where these vessels are present. The objective is to compare the efficacy for ROP between ranibizumab and laser therapy. MATERIAL AND METHODS: Electronic searches will be carried out in medical databases with key words and controlled vocabulary terms. Randomized controlled trials (RCT) will be assessed. The primary outcome will be the full ROP regression. Two reviewers will extract the data using predefined forms and, to assess the quality of the study, we will use RoB 2.0, the tool for randomized controlled trials developed by the Cochrane Collaboration. We used a combination of the inverse-variance approach and random-effects models for the meta-analysis. RESULTS: The eyes of 182 preterm infants who had ranibizumab treatment were assessed in a total of 364 eyes, and 135 infants received laser therapy. The follow-up period was between 6 and 24 months. Ranibizumab was not associated with greater regression of ROP compared to laser therapy in preterm infants (RR: 1.09, CI 95%: 0.95–1.24; p: 0.22). Also, ranibizumab was not associated with recurrence of ROP compared to laser therapy in preterm infants (RR: 3.77, CI 95%: 0.55–25.81; p: 0.22). CONCLUSIONS: The efficacy of ranibizumab compared to laser is very uncertain in terms of ROP regression and decreased ROP recurrence in preterm infants. SYSTEMATIC REVIEW REGISTRATION: identifier PROSPERO (CRD42022324150).
format Online
Article
Text
id pubmed-10436596
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104365962023-08-19 Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis Alva, Niza Martínez, Alex R. Ortiz-Saavedra, Brando Montes-Madariaga, Elizbet S. Cotrina, Alonso Caballero-Alvarado, José A. Sah, Ranjit Barboza, Joshuan J. Front Pediatr Pediatrics Anti-VEGF drugs like ranibizumab can be used to treat retinopathy of prematurity (ROP) by halting the formation of abnormal blood vessels, or lasers can be used to burn the edges of the retina where these vessels are present. The objective is to compare the efficacy for ROP between ranibizumab and laser therapy. MATERIAL AND METHODS: Electronic searches will be carried out in medical databases with key words and controlled vocabulary terms. Randomized controlled trials (RCT) will be assessed. The primary outcome will be the full ROP regression. Two reviewers will extract the data using predefined forms and, to assess the quality of the study, we will use RoB 2.0, the tool for randomized controlled trials developed by the Cochrane Collaboration. We used a combination of the inverse-variance approach and random-effects models for the meta-analysis. RESULTS: The eyes of 182 preterm infants who had ranibizumab treatment were assessed in a total of 364 eyes, and 135 infants received laser therapy. The follow-up period was between 6 and 24 months. Ranibizumab was not associated with greater regression of ROP compared to laser therapy in preterm infants (RR: 1.09, CI 95%: 0.95–1.24; p: 0.22). Also, ranibizumab was not associated with recurrence of ROP compared to laser therapy in preterm infants (RR: 3.77, CI 95%: 0.55–25.81; p: 0.22). CONCLUSIONS: The efficacy of ranibizumab compared to laser is very uncertain in terms of ROP regression and decreased ROP recurrence in preterm infants. SYSTEMATIC REVIEW REGISTRATION: identifier PROSPERO (CRD42022324150). Frontiers Media S.A. 2023-08-04 /pmc/articles/PMC10436596/ /pubmed/37601137 http://dx.doi.org/10.3389/fped.2023.1202927 Text en © 2023 Alva, Martínez, Ortiz-Saavedra, Montes-Madariaga, Cotrina, Caballero-Alvarado, Sah and Barboza. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Alva, Niza
Martínez, Alex R.
Ortiz-Saavedra, Brando
Montes-Madariaga, Elizbet S.
Cotrina, Alonso
Caballero-Alvarado, José A.
Sah, Ranjit
Barboza, Joshuan J.
Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis
title Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis
title_full Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis
title_fullStr Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis
title_full_unstemmed Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis
title_short Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis
title_sort ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436596/
https://www.ncbi.nlm.nih.gov/pubmed/37601137
http://dx.doi.org/10.3389/fped.2023.1202927
work_keys_str_mv AT alvaniza ranibizumabforthetreatmentofretinopathyofprematuritysystematicreviewandmetaanalysis
AT martinezalexr ranibizumabforthetreatmentofretinopathyofprematuritysystematicreviewandmetaanalysis
AT ortizsaavedrabrando ranibizumabforthetreatmentofretinopathyofprematuritysystematicreviewandmetaanalysis
AT montesmadariagaelizbets ranibizumabforthetreatmentofretinopathyofprematuritysystematicreviewandmetaanalysis
AT cotrinaalonso ranibizumabforthetreatmentofretinopathyofprematuritysystematicreviewandmetaanalysis
AT caballeroalvaradojosea ranibizumabforthetreatmentofretinopathyofprematuritysystematicreviewandmetaanalysis
AT sahranjit ranibizumabforthetreatmentofretinopathyofprematuritysystematicreviewandmetaanalysis
AT barbozajoshuanj ranibizumabforthetreatmentofretinopathyofprematuritysystematicreviewandmetaanalysis